清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder: Frequency and Type of Cancer Co-Existence, Antigen Expression and Proof of Paraneoplastic Phenotype (P11-8.018)

视神经脊髓炎 水通道蛋白4 医学 表型 光谱紊乱 抗原 免疫学 抗体 病理 生物 基因 遗传学 精神科
作者
Naga Pradyumna Kothapalli,Yong Xia Guo,Dean M. Wingerchuk,Eoin P. Flanagan,Divyanshu Dubey,Fernando X. Cuascut,Hemali Patel,Nanthaya Tisavipat,Mark Keegan,William Oliver Tobin,Cristina Valencia Sánchez,Claudia Francesca Lucchinetti,Sean Joseph Pittock
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:104 (7_Supplement_1): 2312-
标识
DOI:10.1212/wnl.0000000000209063
摘要

Objective: To report malignancy screening data in a large AQP4+NMOSD cohort and investigate the AQP4 expression in tumor tissues. Background: The link between tumors expressing AQP4 and NMOSD onset is a fascinating area of research. Paraneoplastic AQP4+NMOSD (PAN) was labeled by prior studies to have a male predominance, area postrema syndrome at onset, definite association of adenocarcinomas, without emphasis on demonstrating AQP4 expression on tumors. Design/Methods: Retrospective chart analysis was performed in AQP4+NMOSD cohort; patients with cancers diagnosis independent of the time cutoff from the onset of NMOSD were identified; tumor tissues underwent immunohistochemical (IHC) analysis for AQP4 expression, cases tested positive were classified as PAN. Age-appropriate (AA) malignancy screening data was gathered per American Cancer Society guidelines. Results: 33 NMO patients had coexisting malignancies (male=6, female=27) with median age of onset (MAO) of 57 years (range 15–71), comprising 9% of AQP4-NMOSD cohort. AQP4 expression was present in 4/13 tumors tested. All 4 were women (MOA 57, range 30–59 years), cancers were identified 29 months (range 1–86) after NMOSD onset. Patient 1, with recurrent ON, had serous ovarian adenocarcinoma; Patient 2, with recurrent LETM, had papillary thyroid carcinoma; Patient 3, with area postrema attack, had ductal carcinoma breast. Patient 4, with multifocal attack had poorly differentiated breast carcinoma. AQP4 expression was absent-endometrial adenocarcinomas (2), lung squamous cell carcinoma (1), clear cell renal carcinomas (2), Lymphomas (4). In AQP4+NMOSD cohort (n=394, male=63, female=331), 40% (160, male=36, female=124) were in age of NMOSD onset >50 years subset. Complete AA malignancy screening was pursued in 19% of males, 19% of females; partial AA malignancy screening in 39% of males, 49% of females. Conclusions: Most of the coexisting malignancies are incidental per IHC analysis. PAN has no specific phenotypic preponderance or a definite association with adenocarcinomas. Further proteomic analysis studies are necessary to guide malignancy screening in AQP4+NMOSD. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Kothapalli has nothing to disclose. Yong Guo has nothing to disclose. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers. The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from UCB. Dr. Dubey has received research support from David J. Tomassoni ALS Research Grant Program . Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Cuascut Lassus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Cuascut Lassus has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Cuascut Lassus has received personal compensation in the range of $500-$4,999 for serving as a Speaker with MSAA. Dr. Patel has nothing to disclose. Miss Tisavipat has nothing to disclose. Dr. Keegan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Keegan has received publishing royalties from a publication relating to health care. The institution of Dr. Tobin has received research support from Mallinckrodt. Dr. Tobin has received publishing royalties from a publication relating to health care. Dr. Tobin has received personal compensation in the range of $500-$4,999 for serving as a Speaker with NeurologyLive. Dr. Valencia Sanchez has a non-compensated relationship as a member of the medical advisory board with The MOG Project that is relevant to AAN interests or activities. The institution of Dr. Lucchinetti has received research support from Biogen Idec. The institution of Dr. Lucchinetti has received research support from NIH/NINDS. The institution of Dr. Lucchinetti has received research support from National Institute of Neurological Disorders and Stroke . The institution of Dr. Lucchinetti has received research support from National Multiple Sclerosis Society. The institution of Dr. Lucchinetti has received research support from National Center for Advancing Translational Sciences. Dr. Lucchinetti has received intellectual property interests from a discovery or technology relating to health care. Dr. Lucchinetti has a non-compensated relationship as a Member with National Institute of Neurological Disorders that is relevant to AAN interests or activities. Dr. Lucchinetti has a non-compensated relationship as a Member with Board of Directors, Association of University Professors of Neurology that is relevant to AAN interests or activities. Dr. Lucchinetti has a non-compensated relationship as a Member with Mayo Clinic Board of Trustees that is relevant to AAN interests or activities. Dr. Lucchinetti has a non-compensated relationship as a Member with Mayo Clinic Board of Governors that is relevant to AAN interests or activities. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. The institution of Dr. Pittock has received research support from Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from F. Hoffman/LaRoche/Genentech. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sponge完成签到 ,获得积分10
2秒前
仁爱的元槐完成签到,获得积分10
3秒前
眯眯眼的破茧完成签到,获得积分10
10秒前
XiaonanTang完成签到 ,获得积分10
23秒前
Karl完成签到,获得积分10
29秒前
zzz完成签到,获得积分10
34秒前
QQQQQQ完成签到 ,获得积分10
44秒前
谦让的沛芹完成签到,获得积分10
50秒前
rockyshi完成签到 ,获得积分10
52秒前
yx完成签到 ,获得积分10
53秒前
称心的高丽完成签到 ,获得积分10
56秒前
怕黑的夏之完成签到,获得积分10
1分钟前
n01W97的应助被科研通管家采纳,获得20
1分钟前
1分钟前
领导范儿的应助被科研通管家采纳,获得10
1分钟前
1分钟前
星辰大海的应助被科研通管家采纳,获得10
1分钟前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
共享精神的应助被科研通管家采纳,获得10
1分钟前
脑洞疼的应助被小小采纳,获得10
1分钟前
赘婿的应助被小小采纳,获得10
1分钟前
蔡勇强完成签到 ,获得积分10
1分钟前
王馨完成签到 ,获得积分10
1分钟前
Elsevier大王的应助被小小采纳,获得30
1分钟前
脑洞疼的应助被小小采纳,获得10
1分钟前
自然的妙梦完成签到,获得积分10
1分钟前
粗暴的画板完成签到,获得积分10
2分钟前
cdercder的应助被小小采纳,获得10
2分钟前
领导范儿的应助被依然灬聆听采纳,获得10
2分钟前
科目三的应助被小小采纳,获得10
2分钟前
诚心金渐基完成签到 ,获得积分10
2分钟前
独特的高山完成签到 ,获得积分10
2分钟前
田様的应助被小小采纳,获得10
2分钟前
wcl完成签到,获得积分10
2分钟前
孙文杰完成签到 ,获得积分0
2分钟前
万能图书馆的应助被小小采纳,获得10
2分钟前
可爱沛蓝完成签到 ,获得积分10
2分钟前
隐形曼青的应助被小小采纳,获得10
2分钟前
成就的翠芙完成签到,获得积分10
2分钟前
睡不醒完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834496
捐赠科研通 7783045
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558912
邀请新用户注册赠送积分活动 2481326